Type distribution of human papillomavirus among adult women diagnosed with invasive cervical cancer (stage 1b or higher) in New Zealand

BMC Infectious Diseases

Volumn 14, Issue 1, 2014, Pages

  Sykes, Peter ^a   Gopala, Kusuma ^b   Tan, Ai L ^c   Kenwright, Diane ^d   Petrich, Simone ^e   Molijn, Anco ^f   Chen, Jing ^g  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b GlaxoSmithKline Pharmaceuticals Ltd   (India)

^c NATIONAL WOMEN S HOSPITAL   (New Zealand)

^d UNIVERSITY OF OTAGO   (New Zealand)

^e SOUTHERN DISTRICT HEALTH BOARD   (New Zealand)

^f DDL DIAGNOSTIC LABORATORY   (Netherlands)

^g GLAXOSMITHKLINE   (Singapore)

Author keywords

Epidemiology; Human papillomavirus; Invasive cervical cancer; New Zealand

Indexed keywords

FORMALDEHYDE; PARAFFIN; VIRUS DNA;

ADULT; AGE; ARTICLE; CANCER STAGING; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DNA DETERMINATION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 59; HUMAN TISSUE; IMMUNOASSAY; INFECTION RATE; INFECTION RISK; MAJOR CLINICAL STUDY; MIXED INFECTION; NEW ZEALAND; PAPILLOMAVIRUS INFECTION; POLYMERASE CHAIN REACTION; SPECIES DISTRIBUTION; TUMOR INVASION; UTERINE CERVIX CANCER; VIRUS DETECTION;

ADULT; AGED; AGED, 80 AND OVER; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; NEW ZEALAND; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 84903807534     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-14-374     Document Type: Article

References (36)

1. Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, Ferlay J. Worldwide burden of cervical cancer in 2008. Ann Oncol 2011, 22(12):2675-2686.
2. GLOBOCAN 2008 v2.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet]. [http://globocan.iarc.fr].
3. HPV Information Centre Human Papillomavirus and Related Cancers in Oceania. Summary Report. [http://www.hpvcentre.net/].
4. Cancer: Selected Sites 2009, 2010, 2011. [http://www.health.govt.nz/publication/cancer-selected-sites-2009-2010-2011].
5. National Cervical Screening Programme. [http://www.nsu.govt.nz/current-nsu-programmes/national-cervical-screening-programme.aspx].
6. McLeod M, Harris R, Purdie G, Cormack D, Robson B, Sykes P, Crengle S, Iupati D, Walker N. Improving survival disparities in cervical cancer between Maori and non-Maori women in New Zealand: a national retrospective cohort study. Aust N Z J Public Health 2010, 34(2):193-199.
7. Cervical Screening in New Zealand A brief statistical review of the first decade. [http://www.nsu.govt.nz/files/NCSP/NCSP_statistical_review.pdf].
8. Cancer Trends: Trends in cancer survival by ethnic and socioeconomic group, New Zealand 1991-2004. Wellington: University of Otago and Ministry of Health. [http://www.otago.ac.nz/wellington/otago031532.pdf].
9. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, Snijders PJ, Peto J, Meijer CJ, Munoz N. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189(1):12-19.
10. Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, . International Agency for Research on Cancer Multicenter Cervical Cancer Study G Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003, 348(6):518-527. International Agency for Research on Cancer Multicenter Cervical Cancer Study G.
11. de Sanjose S, Quint WG, Alemany L, Geraets DT, Klaustermeier JE, Lloveras B, Tous S, Felix A, Bravo LE, Shin HR, Vallejos CS, de Ruiz PA, Lima MA, Guimera N, Clavero O, Alejo M, Llombart-Bosch A, Cheng-Yang C, Tatti SA, Kasamatsu E, Iljazovic E, Odida M, Prado R, Seoud M, Grce M, Usubutun A, Jain A, Suarez GA, Lombardi LE, et al. Human papillomavirus genotype attribution in invasive cervical cancer: a retrospective cross-sectional worldwide study. Lancet Oncol 2010, 11(11):1048-1056.
12. The HPV (Human Papillomavirus) Immunisation Programme: National Implementation Strategic Overview. [http://www.health.govt.nz/system/files/documents/pages/national-implementation-strategic-overview_0.pdf].
13. Burd EM. Human papillomavirus and cervical cancer. Clin Microbiol Rev 2003, 16(1):1-17.
14. The New Zealand HPV Project. [http://www.hpv.org.nz/hpv-vaccine/about-hpv-vaccine].
15. HPV immunisation programme. [http://www.health.govt.nz/our-work/preventative-health-wellness/immunisation/hpv-immunisation-programme].
16. Niccolai LM, Russ C, Julian PJ, Hariri S, Sinard J, Meek JI, McBride V, Markowitz LE, Unger ER, Hadler JL, Sosa LE. Individual and geographic disparities in human papillomavirus types 16/18 in high-grade cervical lesions: associations with race, ethnicity, and poverty. Cancer 2013, 119(16):3052-3058.
17. Benedet JL, Bender H, Jones H, Ngan HY, Pecorelli S. FIGO staging classifications and clinical practice guidelines in the management of gynecologic cancers. FIGO Committee on Gynecologic Oncology. Int J Gynaecol Obstet 2000, 70(2):209-262.
18. Kleter B, van Doorn LJ, Schrauwen L, Molijn A, Sastrowijoto S, ter Schegget J, Lindeman J, ter Harmsel B, Burger M, Quint W. Development and clinical evaluation of a highly sensitive PCR-reverse hybridization line probe assay for detection and identification of anogenital human papillomavirus. J Clin Microbiol 1999, 37(8):2508-2517.
19. van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B. Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR. J Clin Microbiol 2006, 44(9):3292-3298.
20. Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003, 88(1):63-73.
21. Williamson D, Nagappan R, Sirikonda R, Rahnama F, Thomas S, Lovell-Smith M, Croxson M. Distribution of HPV genotypes in women with cervical cancer in Auckland, New Zealand; a review of 50 specimens between 2000-2006. Aust N Z J Obstet Gynaecol 2011, 51(1):67-70.
22. Simonella LM, Lewis H, Smith M, Neal H, Bromhead C, Canfell K. Type-specific oncogenic human papillomavirus infection in high grade cervical disease in New Zealand. BMC Infect Dis 2013, 13:114.
23. Guan P, Howell-Jones R, Li N, de Sanjose S, Franceschi S, Clifford GM. Human papillomavirus types in glandular lesions of the cervix: a meta-analysis of published studies. Int J Cancer 2012, 131(10):2349-2359.
24. Stevens MP, Tabrizi SN, Quinn MA, Garland SM. Human papillomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne. Austr Int J Gynecol Cancer 2006, 16(3):1017-1024.
25. Aruhuri B, Tarivonda L, Tenet V, Sinha R, Snijders PJ, Clifford G, Pang J, McAdam M, Meijer CJ, Frazer IH, Franceschi S. Prevalence of cervical human papillomavirus (HPV) infection in Vanuatu. Cancer Prev Res (Phila) 2012, 5(5):746-753.
26. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007, 121(3):621-632.
27. Stevens MP, Garland SM, Tan JH, Quinn MA, Petersen RW, Tabrizi SN. HPV genotype prevalence in women with abnormal pap smears in Melbourne. Austr J Med Virol 2009, 81(7):1283-1291.
28. Bosch FX, Manos MM, Munoz N, Sherman M, Jansen AM, Peto J, Schiffman MH, Moreno V, Kurman R, Shah KV. Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group. J Natl Cancer Inst 1995, 87(11):796-802.
29. Quddus MR, Manna P, Sung CJ, Kerley S, Steinhoff MM, Lawrence WD. Prevalence, distribution, and viral burden of all 15 high-risk human papillomavirus types in adenosquamous carcinoma of the uterine cervix: a multiplex real-time polymerase chain reaction-based study. Hum Pathol 2014, 45:303-309.
30. Pirog EC, Lloveras B2, Molijn A, Tous S, Guimerà N, Alejo M, Clavero O, Klaustermeier J, Jenkins D, Quint WG, Xavier Bosch F, Alemany L, de Sanjosé S, . on behalf of the RIS HPV TT study group HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases. Mod Pathol 2014, doi:10.1038/modpathol.2014.55. [Epub ahead of print], on behalf of the RIS HPV TT study group.
31. Wheeler CM, Hunt WC, Joste NE, Key CR, Quint WG, Castle PE. Human papillomavirus genotype distributions: implications for vaccination and cancer screening in the United States. J Natl Cancer Inst 2009, 101(7):475-487.
32. Munoz N, Bosch FX, Castellsague X, Diaz M, de Sanjose S, Hammouda D, Shah KV, Meijer CJ. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004, 111(2):278-285.
33. de Cremoux P, de la Rochefordiere A, Savignoni A, Kirova Y, Alran S, Fourchotte V, Plancher C, Thioux M, Salmon RJ, Cottu P, Mignot L, Sastre-Garau X. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPV genotype. Int J Cancer 2009, 124(4):778-782.
34. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, Kisseljov F, Durst M, Schneider A, von Knebel DM. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008, 68(1):307-313.
35. Blakely T, Shaw C, Atkinson J, Cunningham R, Sarfati D. Social inequalities or inequities in cancer incidence? Repeated census-cancer cohort studies, New Zealand 1981-1986 to 2001-2004. Cancer Causes Control 2011, 22(9):1307-1318.
36. Young EJ, Tabrizi SN, Brotherton JM, Wark JD, Pyman J, Saville M, Wrede CD, Jayasinghe Y, Tan J, Gertig DM, Pitts M, Garland SM. Measuring effectiveness of the cervical cancer vaccine in an Australian setting (the VACCINE study). BMC Cancer 2013, 13:296.